

# CERAMENT® G with Gentamicin

## VALUE PROPOSITION

CERAMENT® G is the first and only injectable antibiotic eluting bone graft indicated for use in bone infection.

### The Burden of Bone Infection

Despite medical advancements and use of systemic antibiotics, bone infection remains a challenge. Moreover, bone infections are associated with an increased risk of amputation.

- 1 in 5 infections recur<sup>1</sup>
- 2+ surgical interventions typically required<sup>2</sup>
- 20 - 30% long term recurrence rate<sup>3</sup>
- \$51K more treatment costs for infected patients<sup>4</sup>


### A New Patient Friendly and Fiscally Prudent Pathway

CERAMENT® G addresses two clinical needs; bone remodeling and protected bone healing, leading to significant cost savings and improved clinical outcomes.

### CERAMENT® G Dual Mode of Action

#### PROMOTE BONE HEALING


- Proven bone remodeling<sup>5</sup>



#### PROTECT BONE HEALING

- Safe and reproducible local antibiotic delivery<sup>6</sup>


In vitro elution of gentamicin from CERAMENT G<sup>7</sup>



\*The minimum inhibitory concentration (MIC) is the lowest concentration of a chemical, usually a drug, which prevents visible growth of bacterium.<sup>9</sup>

### Enables a Single-Stage Surgical Approach that is Clinically Proven

Managing bone infections is simplified with CERAMENT® G



## CERAMENT® G Helps Reduce Readmissions, Length of Stay and Costs<sup>11</sup>

### Oxford Health Economic Data Publication<sup>11</sup>

**66%** reduction in readmissions<sup>11</sup>

**5X** lower risk of death<sup>11</sup>

**17 fewer bed days<sup>11</sup>**


**\$10,907 direct cost savings per patient from reduced length of stay<sup>11</sup>**

*\* Compared to UK's top 10 osteomyelitis facilities*

### US Based Health Economic Model<sup>12</sup>

**50 - 60%** reduction in surgeries/reinfections<sup>12</sup>

- Improve patient satisfaction
- Limit risk of reimbursement penalties
- Decrease cost of care



### Reimbursement

- **\$4,918** maximum reimbursement
- **ICD-10-PCS Code:** XW0V0P7

### New technology add on payment (NTAP)

- Offsets product cost, reducing financial impact
- Unique ICD-10 Procedure Code
- Supports access to new technology

### REIMBURSEMENT HOTLINE:

**Email:** [usreimbursement@bonesupport.com](mailto:usreimbursement@bonesupport.com)

**Phone:** 1-866-903-2663

### TO ORDER CERAMENT® G:

**Email:** [us.sales@bonesupport.com](mailto:us.sales@bonesupport.com)

**Phone:** 1-877-719-6718

1. Conterno, L.O., Turchi, M.D. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev. 2013;2013(9).
2. Bezstarosti et al. Insights into treatment and outcome of fracture-related infection: a systematic literature review. Arch Orthop Trauma Surg 139, 61–72 (2019).
3. Pande K. Optimal management of chronic osteomyelitis: current perspectives. Orthop Res Rev. 2015;7:71-81.
4. Thakore et al. Sethi MK. Surgical site infection in orthopedic trauma: A case-control study evaluating risk factors and cost. J Clin Orthop Trauma. 2015 Dec;6(4):220-6.
5. Ferguson et al. 'Radiographic and Histological Analysis of a Synthetic Bone Graft Substitute Eluting Gentamicin in the Treatment of Chronic Osteomyelitis'. J. Bone Joint Infect. 2019; 4(2): 76-84.
6. Stravinskas et al. 'Pharmacokinetics of gentamicin eluted from a regenerating bone graft substitute - In vitro and clinical release studies'. Bone Joint Res. 2016; 5:427–435
7. S038/2023.BONESUPPORT data on file.
8. Aureus MBIC level: Mottola et al. 'Susceptibility patterns of Staphylococcus aureus biofilms in diabetic foot infections'. BMC Microbiology 2016; 16:119. <https://core.ac.uk/download/pdf/71740102.pdf>
9. [https://en.wikipedia.org/wiki/Minimum\\_inhibitory\\_concentration](https://en.wikipedia.org/wiki/Minimum_inhibitory_concentration) [accessed 24th September 2019].
10. McNally et al. Mid- to long-term results of single-stage surgery for patients with chronic osteomyelitis using a bioabsorbable gentamicin-loaded ceramic carrier. Bone Joint J. 2022 Sep;104-B(9):1095-1100.
11. Ferguson et al. A retrospective cohort study comparing clinical outcomes and healthcare resource utilisation in patients undergoing surgery for osteomyelitis in England: a case for reorganising orthopaedic infection services. Journal of bone and joint infection vol. 6,5 151-163. 28 Apr. 2021.
12. Carter et al. Cost-Effectiveness of Single Stage Surgery of Osteomyelitis. SOMOS Conference Presentation Session 7A: Research – Trauma, Arizona, 2022. SOMOS 64th Annual Meeting (xcdsystem.com)